Alternatives to Nanograb

Causal AI drug discovery pairing 20+ petabytes of cellular data with human genetics to find true disease targets

Haplotype Labs builds SaaS and community tooling for population genetics, aiming to cut sequencing costs 50–90% and speed polygenic risk modeling.

Nimbus Therapeutics designs highly selective small-molecule drugs for oncology, immunology, and metabolic disease.

Quibim turns MRI, CT and PET scans into regulatory-cleared quantitative imaging biomarkers for prostate, brain, liver, breast and lung.

Cellino's AI-guided optical bioprocessing automates personalized cell therapy manufacturing on the Nebula™ platform.

Recursion runs AI drug discovery as a lab-in-the-loop engine — automated cellular imaging at scale feeding generative chemistry and a clinical pipeline.

Cellbyte is the AI workspace where pharma Pricing & Market Access teams get source-linked HTA and pricing answers in minutes.

Project-based AI biopharma team that delivers decision-grade research, analysis, and computational design in 3–5 days.

AI and computational bionanotechnology R&D partnership that designs field-ready molecular diagnostics for emerging biological threats in days, not 12+ months.

Owkin's K Pro is an autonomous AI scientist agent for biopharma R&D, turning multimodal patient data into drug discovery and clinical trial

Recursion OS pairs automated wet labs with AI models for AI drug discovery at up to 2 million weekly experiments.

Evotec is a life-science partner running AI-assisted drug discovery and Just–Evotec Biologics manufacturing.

Silico is Goodfire's interpretability agent for understanding and debugging the internals of your AI models.

Generative AI drug discovery suite spanning target ID, molecule design, biologics and clinical trial prediction.

Oncology real-world evidence platform combining high-fidelity patient data with AI-assisted cancer research insights.

All-in-human AI foundation models for precision neurology — vBx-1.0 predicts brain activity and therapy response from a blood draw.

Iktos pairs generative AI with robotic lab automation to compress small-molecule drug discovery.

Renamed: Deep 6 AI was acquired by Tempus AI in March 2025 and its trial matching folded into Tempus.

Physics-based molecular simulation with AI for drug discovery and materials design.

Benchling unifies ELN, LIMS, and AI agents for biotech R&D in one cloud platform.

FDA-cleared AI for cancer pathology: prostate, breast, GI and pan-cancer detection on H&E slides, plus Virchow foundation models for research.

Tempus pairs tumor DNA/RNA sequencing with AI precision oncology analytics to surface treatment and trial matches

AI protein engineering that optimizes binding, stability, activity, and expression across wet-lab rounds.

BenevolentAI applies a decade-built biomedical knowledge graph to drug target discovery and repurposing for biopharma R&D teams.

PathAI's AISight Dx brings FDA-cleared digital pathology and AI biomarker algorithms to labs and biopharma trials.

Dotmatics Luma Agent: agentic AI for regulated R&D that plans, executes, and documents scientific data analysis

AI drug discovery engine pairing 2M weekly automated lab experiments with a 50+ PB proprietary dataset.

Automated cloud lab for protein validation — binding, expression and thermostability assays with data back in as little as 3 days

SciSpace BioMed Agent runs multi-omics, variant prioritization, and drug repurposing analysis from plain-language biomedical prompts.

WhiteLab Genomics' ALFRED platform predicts and optimizes molecular constructs for gene and RNA therapies before synthesis